drugset / Trial / NCT04612504
SynOV1.1 Intratumoral Injection Study
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase I, open-label, multicenter study to characterize safety and tolerability, evaluate biodistribution, biological effects and immunogenicity, and evaluate the preliminary clinical efficacy of SynOV1.1 in participants with AFP positive solid tumors.
Timeline
- Start
- 2022-06-23
- Primary completion
- 2023-12-30
- Completion
- 2024-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SynOV1.1 | Unknown | 3e+11 unknown | Other |
| Subject | SynOV1.1 | Unknown | 1e+12 unknown | Other |
| Subject | SynOV1.1 | Unknown | 3e+12 unknown | Other |